Please check your internet connection and try again.
## Ecospirin (Aspirin Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, which may reduce gastric irritation compared to non-enteric-coated formulations.
### Primary Indications
* **Pain and inflammation:** Mild to moderate pain, fever, and inflammatory conditions.
* **Cardiovascular prophylaxis:** Prevention of myocardial infarction and stroke in patients with a history of cardiovascular disease. Low-dose aspirin is commonly used for this purpose.
### Adult Dosing
Dosing varies significantly by indication.
* **Pain/Inflammation:** Typically 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose generally not to exceed 4 g.
* **Cardiovascular Prophylaxis:** Commonly 75 mg to 100 mg once daily. Some guidelines may suggest up to 325 mg once daily. The precise dose and indication should be confirmed with current clinical guidelines and patient-specific risk factors.
### Pediatric Dosing
Aspirin is generally **not recommended** in children and adolescents due to the risk of Reye's syndrome, a rare but serious condition, especially during viral illnesses such as influenza or chickenpox. If aspirin is deemed absolutely necessary and no alternatives exist, consultation with a pediatrician is essential. Dosing, if used, would be weight-based and carefully monitored, but established guidelines are limited due to safety concerns.
### Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised, particularly with severe impairment, due to potential for accumulation and adverse effects.
### Contraindications
* Known hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active peptic ulcer disease or gastrointestinal bleeding.
* History of aspirin-induced asthma, urticaria, or other allergic-type reactions.
* Certain bleeding disorders.
* Severe hepatic or renal impairment.
* Children and adolescents with viral infections (risk of Reye's syndrome).
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis.
* **Hypersensitivity:** Bronchospasm (aspirin-exacerbated respiratory disease), urticaria, angioedema.
* **Other:** Tinnitus, dizziness, headache.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives:** May reduce the efficacy of some antihypertensive agents.
* **Methotrexate:** Increased risk of methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** May decrease the efficacy of uricosuric agents.
* **Alcohol:** Increased risk of GI irritation and bleeding.
### Monitoring
* **GI symptoms:** Monitor for signs and symptoms of GI bleeding (melena, hematemesis, abdominal pain).
* **Bleeding:** Monitor for unusual bruising or bleeding.
* **Renal function:** Monitor periodically, especially in patients with pre-existing renal disease or those on long-term therapy.
* **Hepatic function:** Monitor periodically, especially with high doses or prolonged use.
* **Tinnitus:** May indicate toxicity.
### Clinical Pearls
* The enteric coating allows for once-daily dosing for cardiovascular prophylaxis but may delay onset of analgesic/anti-inflammatory effects.
* Enteric coating does not eliminate the risk of GI bleeding, although it may reduce it compared to non-enteric-coated aspirin.
* Patients should be advised to take enteric-coated aspirin with a full glass of water and avoid crushing or chewing the tablets to preserve the coating.
* Discontinue aspirin at least 5-7 days prior to elective surgery, unless otherwise directed by the prescriber.
* Consider co-prescription of a proton pump inhibitor (PPI) or H2 blocker for patients at high risk of GI bleeding.
***
**Disclaimer:** This information is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional and review the most current prescribing information for the specific product being used before making any treatment decisions. Dosage and indications can vary based on local guidelines and individual patient factors.
